All News
What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II RCT. N=78, multi dose phase II RCT. All doses improved DAS28. Dosing interval may be prolonged over time. Awaiting phase 3. Abst#2008 #ACR22 @RheumNow https://t.co/IrzflycKZp
Janet Pope Janetbirdope ( View Tweet)
#abst2132 #acr22 @rheumnow safety of Deucravacitinib Ph2PsA&ph3PSO trial: no Δ from BL in hematology, chemistry, or lipid labs. JAK 1/2/3 Effects on hem, hepatic, CPK, and cholesterol lab parameters not observed over 16 wks of DEUC at doses up to 12 mg QD & in combo w/csDMARDs. https://t.co/bjGEYp4GcJ
Olga Petryna DrPetryna ( View Tweet)
Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ
Richard Conway RichardPAConway ( View Tweet)
Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Incident aneurysms rare 8%. Older age and secondary cause assoc greater likelyhood improvement, smokers 2 times less likely. @RheumNow #ACR22 Abstr#1576 https://t.co/jS9djx3ZtU https://t.co/OFW2Jk7gGW
Richard Conway RichardPAConway ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Crit #ACR22
Entry: Clinical & +aPL w/in 3 yr
Then: Additive crit
-Don't count other cause
Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology
Lab: +LA, aCL/B2GP IgM/IgG/titer
Total: 3+ clin, 3+ lab
@RheumNow https://t.co/YeKW0orjZC
Eric Dein ericdeinmd ( View Tweet)
⬆️ serum anti-CCP3 Ab, absence IA
👉 StopRA trial - ironically stopped🛑
❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA
👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs
#ACR22 @RheumNow Abst#1604
Patricia Harkins DrTrishHarkins ( View Tweet)
“As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, on how rheumatologists should not let fear of legal consequences interfere w/practicing high quality evidenced based medicine for our patients #ReproductiveRheum #ACR22 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN
Richard Conway RichardPAConway ( View Tweet)
CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow
https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc
Dr. Rachel Tate uptoTate ( View Tweet)
Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compared to remission and HCs. Correlates disease activity. Not affected by IL6i. @RheumNow #ACR22 Abstr#1573 https://t.co/uJAFHQpOlu https://t.co/PNX0puOeCn
Richard Conway RichardPAConway ( View Tweet)
Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 person years (incidence rate 0.44/1000 py); PJP prophylx cause neutropenia (IRR 4.7), leukopenia (IRR 4.0), C diff (IRR 3.9), hyperkalemia (IRR 3.7) abst#1594 ACR#22 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
#abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO
Olga Petryna DrPetryna ( View Tweet)
Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x
Richard Conway RichardPAConway ( View Tweet)
BE COMPLETE study:
Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals.
Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK
Robert B Chao, MD doctorRBC ( View Tweet)
Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy
Dr. Rachel Tate uptoTate ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Lab Domains:
LAC not always feasible to recheck
aCL, aB2GP IgG higher risk, higher titers (>40U)
@RheumNow https://t.co/rcQaqrtDN5
Eric Dein ericdeinmd ( View Tweet)
The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt
Dr. Rachel Tate uptoTate ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57% vs 46%;OR=1.37 95%CI[1.12-1.69]. Elucidates pathophysiology but also possible treatment rationale @RheumNow #ACR22 Abstr#1123 https://t.co/TAA0rODSmV https://t.co/2TjSY4CXDL
Richard Conway RichardPAConway ( View Tweet)
#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8
Olga Petryna DrPetryna ( View Tweet)
RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL
Dr. Rachel Tate uptoTate ( View Tweet)